Skip to main content
Erschienen in: Archives of Osteoporosis 1/2020

01.12.2020 | Original Article

Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

verfasst von: Yi Ting Chau, Nazrul Nashi, Lawrence Siu-Chun Law, Raymond Kai Heng Goh, Selena Xueli Choo, Santhosh Kumar Seetharaman

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Summary

Undertreatment of osteoporosis after hip fracture increases the risk of death, disability, recurrent osteoporotic fractures, and financial burden. Only half were compliant with osteoporosis medications. Elderly patients were less persistent and compliant to treatment. Denosumab was associated with a higher proportion of days covered by osteoporosis medications than oral bisphosphonates.

Purpose

The aim of this study was to identify factors that contributed to the initiation of osteoporosis medications following hip fracture as well as the compliance and persistence to osteoporosis medications.

Methods

Clinical data of 532 patients older than 50 years old admitted for surgical fixation of hip fractures were reviewed. Three hundred forty-seven had sufficient data for analysis after excluding patients with non-fragility fractures. Prescription for any osteoporosis medication in the year following hip fracture as well as compliance to treatment was evaluated.

Results

Only 40.3% of patients were prescribed with osteoporosis medication within 1 year post-hip fracture. Females (p = 0.020) performing dual-energy x-ray absorptiometry scan (p < 0.001) and 25 hydroxyvitamin D levels testing post-hip fracture (p < 0.027) were independent determinants of increased likelihood of being prescribed with osteoporosis medication. Patients with proportion of days covered (PDC) ≥ 0.8 (or 80% of days covered in a year) were defined as compliant. Overall, only 49.7% of the patients were compliant with osteoporosis medications. Elderly patients aged 70–79 years (p = 0.002) and males (p = 0.017) were less persistent with osteoporosis treatment when compared with patients aged < 69 years and females. The compliance was poorer in patients aged 70–79 years (p = 0.026) as compared with those under 69 years of age. Statistically significant difference (p = 0.032) was observed between mean PDC of oral bisphosphonates (0.66) and denosumab (0.83). Only 39.3% of patients were persistent with treatment at 1 year.

Conclusion

Our findings demonstrate the urgent need to increase awareness through a structured protocol of osteoporosis treatment. A multi-disciplinary Fracture Liaison Service should be set up to ensure compliance to osteoporosis medication post-hip fracture.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ng C, Lau T, Ko Y (2017) Cost of osteoporotic fractures in Singapore. Value Health Reg Issues 12:27–35PubMed Ng C, Lau T, Ko Y (2017) Cost of osteoporotic fractures in Singapore. Value Health Reg Issues 12:27–35PubMed
4.
Zurück zum Zitat Brown JP, Josse RG (2002) 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:1–34 Brown JP, Josse RG (2002) 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:1–34
5.
Zurück zum Zitat Chandran M, Tan MZW, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures - An ‘OPTIMAL’ model of care from Singapore. Osteoporosis Int 24:2809–2817 Chandran M, Tan MZW, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures - An ‘OPTIMAL’ model of care from Singapore. Osteoporosis Int 24:2809–2817
6.
Zurück zum Zitat Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937PubMed Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937PubMed
7.
Zurück zum Zitat Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526PubMedPubMedCentral Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526PubMedPubMedCentral
8.
Zurück zum Zitat Klop C, Gibson-Smith D, Elders PJM, Welsing PMJ, Leufkens HGM, Harvey NC, Bijlsma JWJ, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporos Int 26:1919–1928PubMedPubMedCentral Klop C, Gibson-Smith D, Elders PJM, Welsing PMJ, Leufkens HGM, Harvey NC, Bijlsma JWJ, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporos Int 26:1919–1928PubMedPubMedCentral
9.
Zurück zum Zitat Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA - J Am Med Assoc 302:1573–1579 Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA - J Am Med Assoc 302:1573–1579
10.
Zurück zum Zitat Ahmed L, Center J, Bjørnerem Å et al (2013) Progressively increasing fracture risk with advancing age after initial incident fragility fracture: The Tromso Study. J Bone Miner Res 28:2214–2221PubMed Ahmed L, Center J, Bjørnerem Å et al (2013) Progressively increasing fracture risk with advancing age after initial incident fragility fracture: The Tromso Study. J Bone Miner Res 28:2214–2221PubMed
11.
Zurück zum Zitat Merchant RA, Lui KL, Ismail NH, Wong HP, Sitoh YY (2005) The relationship between postoperative complications and outcomes after hip fracture surgery. Ann Acad Med Singapore 34:163–168PubMed Merchant RA, Lui KL, Ismail NH, Wong HP, Sitoh YY (2005) The relationship between postoperative complications and outcomes after hip fracture surgery. Ann Acad Med Singapore 34:163–168PubMed
12.
Zurück zum Zitat Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53–62PubMed Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53–62PubMed
13.
Zurück zum Zitat Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581–593PubMed Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581–593PubMed
14.
Zurück zum Zitat Varacallo MA, Fox EJ (2014) Osteoporosis and its complications. Med Clin North Am 98:817–831PubMed Varacallo MA, Fox EJ (2014) Osteoporosis and its complications. Med Clin North Am 98:817–831PubMed
15.
Zurück zum Zitat Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35PubMed Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35PubMed
16.
Zurück zum Zitat Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs - an analysis using national health databases. Osteoporos Int 24:2639–2647PubMed Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs - an analysis using national health databases. Osteoporos Int 24:2639–2647PubMed
17.
Zurück zum Zitat Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 17:43–49 Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 17:43–49
18.
Zurück zum Zitat McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMed McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMed
19.
Zurück zum Zitat Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMed Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMed
20.
Zurück zum Zitat Cheen MHH, Kong MC, Zhang RF, Tee FMH, Chandran M (2012) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 23:1053–1060PubMed Cheen MHH, Kong MC, Zhang RF, Tee FMH, Chandran M (2012) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 23:1053–1060PubMed
21.
Zurück zum Zitat Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381PubMedPubMedCentral Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381PubMedPubMedCentral
24.
Zurück zum Zitat Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 22:397–403PubMedPubMedCentral Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 22:397–403PubMedPubMedCentral
25.
Zurück zum Zitat Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12PubMed Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12PubMed
26.
Zurück zum Zitat Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155PubMed Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155PubMed
27.
Zurück zum Zitat Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMed Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMed
28.
Zurück zum Zitat Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172PubMed Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172PubMed
29.
Zurück zum Zitat Panneman MJM, Lips P, Sen SS, Herings RMC (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124PubMed Panneman MJM, Lips P, Sen SS, Herings RMC (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124PubMed
30.
Zurück zum Zitat Bor A, Matuz M, Gyimesi N, Biczók Z, Soós GDP (2015) Gender inequalities in the treatment of osteoporosis. Maturitas 80:162–169PubMed Bor A, Matuz M, Gyimesi N, Biczók Z, Soós GDP (2015) Gender inequalities in the treatment of osteoporosis. Maturitas 80:162–169PubMed
31.
Zurück zum Zitat Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396PubMed Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396PubMed
32.
Zurück zum Zitat Nayak S, Roberts MS, Chang CCH, Greenspan SL (2010) Health beliefs about osteoporosis and osteoporosis screening in older women and men. Health Educ J 69:267–276PubMedPubMedCentral Nayak S, Roberts MS, Chang CCH, Greenspan SL (2010) Health beliefs about osteoporosis and osteoporosis screening in older women and men. Health Educ J 69:267–276PubMedPubMedCentral
33.
Zurück zum Zitat Johnson CS, McLeod W, Kennedy L, McLeod K (2008) Osteoporosis health beliefs among younger and older men and women. Heal Educ Behav 35:721–733 Johnson CS, McLeod W, Kennedy L, McLeod K (2008) Osteoporosis health beliefs among younger and older men and women. Heal Educ Behav 35:721–733
34.
Zurück zum Zitat Marsh D, Åkesson K, Beaton D et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporosis Int 22(7):2051–2065 Marsh D, Åkesson K, Beaton D et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporosis Int 22(7):2051–2065
35.
Zurück zum Zitat Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390PubMedPubMedCentral Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390PubMedPubMedCentral
36.
Zurück zum Zitat Beaton DE, Dyer S, Jiang D et al (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int 25:289–296PubMed Beaton DE, Dyer S, Jiang D et al (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int 25:289–296PubMed
37.
Zurück zum Zitat Roux C, Briot K (2020) The crisis of inadequate treatment in osteoporosis. Lancet Rheumatol 2:110–119 Roux C, Briot K (2020) The crisis of inadequate treatment in osteoporosis. Lancet Rheumatol 2:110–119
38.
Zurück zum Zitat Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52:1031–1041PubMed Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52:1031–1041PubMed
39.
Zurück zum Zitat Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231PubMed Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231PubMed
40.
Zurück zum Zitat Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMed Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMed
41.
Zurück zum Zitat Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340–347PubMedPubMedCentral Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340–347PubMedPubMedCentral
42.
Zurück zum Zitat Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876–883PubMedPubMedCentral Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876–883PubMedPubMedCentral
43.
Zurück zum Zitat Saw SM, Hong CY, Lee J, Wong ML, Chan MF, Cheng A, Leong KH (2003) Awareness and health beliefs of women towards osteoporosis. Osteoporos Int 14:595–601PubMed Saw SM, Hong CY, Lee J, Wong ML, Chan MF, Cheng A, Leong KH (2003) Awareness and health beliefs of women towards osteoporosis. Osteoporos Int 14:595–601PubMed
44.
Zurück zum Zitat Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMed Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMed
45.
Zurück zum Zitat Chen I, Chiang C, Li Y et al (2015) Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporosis Int 26(2):681–688 Chen I, Chiang C, Li Y et al (2015) Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporosis Int 26(2):681–688
Metadaten
Titel
Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore
verfasst von
Yi Ting Chau
Nazrul Nashi
Lawrence Siu-Chun Law
Raymond Kai Heng Goh
Selena Xueli Choo
Santhosh Kumar Seetharaman
Publikationsdatum
01.12.2020
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2020
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-020-00816-2

Weitere Artikel der Ausgabe 1/2020

Archives of Osteoporosis 1/2020 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.